B型慢性肝炎の世界市場レポート 2024年

B型慢性肝炎の市場規模は、今後数年間で安定した成長が見込まれます。2028年にはCAGR4.3％で44億7,000万米ドルに成長します。この予測期間における成長機会は、新興市場におけるビジネス機会の拡大、政府の支援政策と資金援助、診断とスクリーニング技術の進歩、医療支出の増加、戦略的パートナーシップとコラボレーションの増加、高齢者人口の増加、社会的認知度向上キャンペーンによって促進されます。この期間に予想される主要動向には、根治的治療へのシフト、新興市場への進出、診断・スクリーニング技術の向上、パートナーシップと協力関係の促進、患者中心の医療への注力などがあります。

B型慢性肝炎感染症の高い有病率が、B型慢性肝炎ウイルス市場の今後の成長を牽引すると予想されます。B型肝炎は、B型肝炎ウイルス（HBV）によって引き起こされる肝臓感染症で、ワクチン接種によって予防することができます。B型肝炎の感染率の増加は、特に低・中所得国で顕著であり、ワクチン接種率が低いため、人口の大部分が無防備のままであり、感染率の上昇につながっています。この感染率の上昇により、診断試験や治療法に対する需要が高まっています。例えば、スウェーデンに本部を置く欧州疾病予防管理センターによると、2021年に東欧の30加盟国で記録されたB型肝炎ウイルス（HBV）感染症例は16,187件でした。総患者数は1万5,380人で、2020年の1万4,332人に比べ、人口10万人当たりの粗感染率は4.7人です。したがって、B型肝炎感染の高い有病率がB型慢性肝炎ウイルス市場を押し上げると考えられます。

B型慢性肝炎市場の主要企業は、技術力と市場リーチを強化するために戦略的パートナーシップを採用しています。戦略的パートナーシップとは、2つ以上の組織が共通の目標や目的を達成するために、それぞれのリソース、専門知識、努力を結集する協力関係を指します。例えば、2021年1月、米国のバイオ医薬品企業であるGilead Sciences Inc.は、米国のバイオテクノロジー企業であるVIR Biotechnologyと提携し、B型慢性肝炎ウイルス（HBV）の機能的治癒を目指した新規併用療法を探求しています。両社は、Gileadの治験用TLR-8アゴニスト、セルガントリモド、VIRの治験用siRNA、VIR-2218、市販のPD-1拮抗薬の様々な組み合わせを評価する第2相試験を開始します。さらに、治療経験のある患者にはGileadのVemlidy（テノホビルアラフェナミドフマル酸塩、TAF）が投与される可能性があります。本試験の第一目標は、治療終了後の血清からB型肝炎表面抗原（HBsAg）とHBV DNAが消失することを特徴とする機能的治癒を達成する患者の割合を決定することです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界の市場規模と成長

• 世界のB型慢性肝炎市場：促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界のB型慢性肝炎市場の実績：規模と成長、2018～2023年
• 世界のB型慢性肝炎市場の予測：規模と成長、2023～2028年、2033年

第6章 市場セグメンテーション

• 世界のB型慢性肝炎市場：薬剤クラス別、実績と予測、2018～2023年、2023～2028年、2033年
• 抗ウイルス薬
• 免疫調節剤
• 世界のB型慢性肝炎市場：性別、実績と予測、2018～2023年、2023～2028年、2033年
• 男性
• 女性
• 世界のB型慢性肝炎市場：流通チャネル別、実績と予測、2018～2023年、2023～2028年、2033年
• 病院薬局
• ドラッグストアと薬局
• オンラインプロバイダー

第7章 地域別・国別分析

• 世界のB型慢性肝炎市場：地域別、実績と予測、2018～2023年、2023～2028年、2033年
• 世界のB型慢性肝炎市場：国別、実績と予測、2018～2023年、2023～2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• B型慢性肝炎市場：競合情勢
• B型慢性肝炎市場：企業プロファイル
  • Pfizer Inc.
  • F Hoffmann-La Roche Ltd
  • Merck & Co Inc
  • Bristol-Myers Squibb Company
  • Novartis AG

第31章 その他の大手企業と革新的企業

• GlaxoSmithKline plc
• Dynavax Technologies Corporation
• Gilead Sciences Inc
• Viatris Inc.
• Teva Pharmaceutical Industries Limited
• Sun Pharmaceutical Industries Ltd.
• Aurobindo Pharma Limited
• Dr. Reddy's Laboratories Ltd.
• Apotex Corp
• Cipla Ltd
• Hikma Pharmaceuticals
• Lupin Pharmaceuticals Inc
• Vir Biotechnology Inc
• VBI Vaccines Inc
• Shenzhen Hepalink Pharmaceutical Co. Ltd.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の展望と潜在的な分析

第36章 付録

Chronic hepatitis B results from a prolonged infection with the hepatitis B virus (HBV), lasting more than six months. It can potentially cause severe liver damage, liver failure, or liver cancer. While often asymptomatic for years, it can be identified through blood tests and requires ongoing management with antiviral medications and regular monitoring.

In treating chronic hepatitis B, medications primarily consist of antivirals and immunomodulators. Antivirals are specifically designed to hinder the replication and growth of viruses. They play a crucial role in managing chronic hepatitis B by reducing the viral load in the liver and slowing the progression of liver damage.

The chronic hepatitis B market research report is one of a series of new reports from the business research company that provides chronic hepatitis B market statistics, including chronic hepatitis B industry global market size, regional shares, competitors with an chronic hepatitis B market share, detailed chronic hepatitis B market segments, market trends and opportunities, and any further data you may need to thrive in the chronic hepatitis B industry. This chronic hepatitis B market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The chronic hepatitis B market size has grown steadily in recent years. It will grow from $3.62 billion in 2023 to $3.77 billion in 2024 at a compound annual growth rate (CAGR) of 4.2%. The growth during the historic period was driven by advancements in antiviral therapy, increased efforts from governments and NGOs, enhanced diagnostic techniques, a rising incidence of HIV, and heightened awareness.

The chronic hepatitis B market size is expected to see steady growth in the next few years. It will grow to $4.47 billion in 2028 at a compound annual growth rate (CAGR) of 4.3%. Anticipated growth in the forecast period will be fueled by expanding opportunities in emerging markets, supportive government policies and funding, advancements in diagnostics and screening technologies, rising healthcare spending, increased strategic partnerships and collaborations, a growing elderly population, and heightened public awareness campaigns. Key trends expected in this period include a shift towards curative treatments, expansion into emerging markets, improvements in diagnostics and screening, fostering partnerships and collaborations, and a focus on patient-centered care.

The high prevalence of chronic hepatitis B infection is anticipated to drive the growth of the chronic hepatitis B virus market in the future. Hepatitis B is a liver infection caused by the hepatitis B virus (HBV) and can be prevented through vaccination. The increase in hepatitis B infection rates is particularly evident in low- and middle-income countries, where low vaccination coverage leads to higher transmission rates as large portions of the population remain unprotected. This rising infection rate increases the demand for diagnostic tests and treatment options. For example, according to the European Centre for Disease Prevention and Control, a Sweden-based agency, there were 16,187 cases of hepatitis B virus (HBV) infection recorded in 30 Eastern European Member States in 2021. The total cases amount to 15,380, which is a crude rate of 4.7 cases per 100,000 people, compared to 14,332 cases in 2020. Thus, the high prevalence of hepatitis B infection will boost the chronic hepatitis B virus market.

Major companies in the chronic hepatitis B market are adopting strategic partnerships to enhance their technological capabilities and market reach. A strategic partnership involves a collaborative relationship between two or more organizations that combine their resources, expertise, and efforts to achieve common goals or objectives. For instance, in January 2021, Gilead Sciences Inc., a US-based biopharmaceutical company, collaborated with VIR Biotechnology, a US-based biotech company, to explore novel combination therapies aimed at achieving a functional cure for chronic hepatitis B virus (HBV). They will start a Phase 2 trial assessing various combinations of Gilead's investigational TLR-8 agonist, selgantolimod, Vir's investigational siRNA, VIR-2218, and a commercially available PD-1 antagonist. Additionally, treatment-experienced patients may receive Gilead's Vemlidy (tenofovir alafenamide fumarate, TAF). The primary goal of the trial is to determine the percentage of patients achieving a functional cure, characterized by the disappearance of hepatitis B surface antigen (HBsAg) and HBV DNA from the serum off-therapy.

In November 2023, GSK plc, a pharmaceutical company headquartered in the UK, acquired exclusive rights to a hepatitis B therapy from Janssen Pharmaceuticals for $1 billion. The acquisition includes the rights to JNJ-3989 (also known as ARO-HBV), an antisense oligonucleotide drug. Through this acquisition, GSK aims to enrich its portfolio and reinforce its position in the treatment of chronic hepatitis B by introducing a promising new therapy. Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson based in Belgium, specializes in developing treatments for a range of serious and complex diseases, including infectious diseases such as chronic hepatitis B.

Major companies operating in the chronic hepatitis b market are Pfizer Inc., F Hoffmann-La Roche Ltd, Merck & Co Inc, Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Dynavax Technologies Corporation, Gilead Sciences Inc, Viatris Inc., Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd., Apotex Corp, Cipla Ltd, Hikma Pharmaceuticals, Lupin Pharmaceuticals Inc, Vir Biotechnology Inc, VBI Vaccines Inc, Shenzhen Hepalink Pharmaceutical Co. Ltd., Accord Healthcare Inc, Par Pharmaceutical Inc, Arrowhead Pharmaceuticals Inc, ViiV Healthcare, Arbutus Biopharma Corporation, Ascentage Pharma, ENYO Pharma, Zydus Pharmaceuticals Inc, Nucorion Pharmaceuticals

North America was the largest region in the chronic hepatitis B market in 2023. The regions covered in the chronic hepatitis b market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the chronic hepatitis b market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The chronic hepatitis B market consists of revenues earned by entities by providing services such as diagnostic testing, treatments, liver function monitoring, patient education, and support programs.The market value includes the value of related goods sold by the service provider or included within the service offering. The chronic hepatitis B market also includes sales of medications, interferons, liver transplant medications, diagnostic kits, liver biopsy equipment, and HBV vaccines. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Chronic Hepatitis B Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on chronic hepatitis B market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for chronic hepatitis B ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The chronic hepatitis B market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Antivirals; Immune Modulators
• 2) By Gender: Male; Female
• 3) By Distribution Channel: Hospital Pharmacies; Drug Stores And Retail Pharmacies; Online Providers
• Companies Mentioned: Pfizer Inc.; F Hoffmann-La Roche Ltd; Merck & Co Inc; Bristol-Myers Squibb Company; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Chronic Hepatitis B Market Characteristics

3. Chronic Hepatitis B Market Trends And Strategies

4. Chronic Hepatitis B Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Chronic Hepatitis B Market Size and Growth

• 5.1. Global Chronic Hepatitis B Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Chronic Hepatitis B Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Chronic Hepatitis B Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Chronic Hepatitis B Market Segmentation

• 6.1. Global Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Antivirals
• Immune Modulators
• 6.2. Global Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Male
• Female
• 6.3. Global Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospital Pharmacies
• Drug Stores And Retail Pharmacies
• Online Providers

7. Chronic Hepatitis B Market Regional And Country Analysis

• 7.1. Global Chronic Hepatitis B Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Chronic Hepatitis B Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Chronic Hepatitis B Market

• 8.1. Asia-Pacific Chronic Hepatitis B Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Chronic Hepatitis B Market

• 9.1. China Chronic Hepatitis B Market Overview
• 9.2. China Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Chronic Hepatitis B Market

• 10.1. India Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Chronic Hepatitis B Market

• 11.1. Japan Chronic Hepatitis B Market Overview
• 11.2. Japan Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Chronic Hepatitis B Market

• 12.1. Australia Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Chronic Hepatitis B Market

• 13.1. Indonesia Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Chronic Hepatitis B Market

• 14.1. South Korea Chronic Hepatitis B Market Overview
• 14.2. South Korea Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Chronic Hepatitis B Market

• 15.1. Western Europe Chronic Hepatitis B Market Overview
• 15.2. Western Europe Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Chronic Hepatitis B Market

• 16.1. UK Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Chronic Hepatitis B Market

• 17.1. Germany Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Chronic Hepatitis B Market

• 18.1. France Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Chronic Hepatitis B Market

• 19.1. Italy Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Chronic Hepatitis B Market

• 20.1. Spain Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Chronic Hepatitis B Market

• 21.1. Eastern Europe Chronic Hepatitis B Market Overview
• 21.2. Eastern Europe Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Chronic Hepatitis B Market

• 22.1. Russia Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Chronic Hepatitis B Market

• 23.1. North America Chronic Hepatitis B Market Overview
• 23.2. North America Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Chronic Hepatitis B Market

• 24.1. USA Chronic Hepatitis B Market Overview
• 24.2. USA Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Chronic Hepatitis B Market

• 25.1. Canada Chronic Hepatitis B Market Overview
• 25.2. Canada Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Chronic Hepatitis B Market

• 26.1. South America Chronic Hepatitis B Market Overview
• 26.2. South America Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Chronic Hepatitis B Market

• 27.1. Brazil Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Chronic Hepatitis B Market

• 28.1. Middle East Chronic Hepatitis B Market Overview
• 28.2. Middle East Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Chronic Hepatitis B Market

• 29.1. Africa Chronic Hepatitis B Market Overview
• 29.2. Africa Chronic Hepatitis B Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Chronic Hepatitis B Market, Segmentation By Gender, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Chronic Hepatitis B Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Chronic Hepatitis B Market Competitive Landscape And Company Profiles

• 30.1. Chronic Hepatitis B Market Competitive Landscape
• 30.2. Chronic Hepatitis B Market Company Profiles
  • 30.2.1. Pfizer Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. F Hoffmann-La Roche Ltd
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Merck & Co Inc
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Bristol-Myers Squibb Company
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Novartis AG
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Chronic Hepatitis B Market Other Major And Innovative Companies

• 31.1. GlaxoSmithKline plc
• 31.2. Dynavax Technologies Corporation
• 31.3. Gilead Sciences Inc
• 31.4. Viatris Inc.
• 31.5. Teva Pharmaceutical Industries Limited
• 31.6. Sun Pharmaceutical Industries Ltd.
• 31.7. Aurobindo Pharma Limited
• 31.8. Dr. Reddy's Laboratories Ltd.
• 31.9. Apotex Corp
• 31.10. Cipla Ltd
• 31.11. Hikma Pharmaceuticals
• 31.12. Lupin Pharmaceuticals Inc
• 31.13. Vir Biotechnology Inc
• 31.14. VBI Vaccines Inc
• 31.15. Shenzhen Hepalink Pharmaceutical Co. Ltd.

32. Global Chronic Hepatitis B Market Competitive Benchmarking

33. Global Chronic Hepatitis B Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Chronic Hepatitis B Market

35. Chronic Hepatitis B Market Future Outlook and Potential Analysis

• 35.1 Chronic Hepatitis B Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Chronic Hepatitis B Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Chronic Hepatitis B Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer